Three different dose groups of hMaxi-K will be tested in this study consisting of 5000, 10,000 and 15,000 micrograms. hMaxi-K will be given as a single administration into the bladder through a catheter. Each women's participation in the study will last for up to 24 weeks (followed by an additional 18 month follow-up period).